Compare KRMD & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | CMPX |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.5M | 203.5M |
| IPO Year | 2019 | 2020 |
| Metric | KRMD | CMPX |
|---|---|---|
| Price | $3.03 | $0.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $6.25 | $5.50 |
| AVG Volume (30 Days) | 226.7K | ★ 3.9M |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,127,366.00 | N/A |
| Revenue This Year | $16.78 | N/A |
| Revenue Next Year | $17.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.98 | $1.08 |
| 52 Week High | $6.61 | $6.88 |
| Indicator | KRMD | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 24.92 | 16.38 |
| Support Level | N/A | N/A |
| Resistance Level | $3.41 | $2.08 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 3.06 | 0.00 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.